Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025
Can Eptifibatide Rewrite the NSTEMI Story? (Eptifibatide vs. Standard Care for NSTEMI: A 5-Year Analysis of Major Adverse Cardiovascular Events).
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kalhor Parvin, Nowrouzi Pargol, Ghahari Parichehr, Mehrani Mehdi
Аннотация
BACKGROUND: Coronary artery disease (CAD) is a leading cause of death worldwide. Among acute coronary syndromes, non-ST-elevation myocardial infarction (NSTEMI) poses a higher long-term risk than ST-elevation myocardial infarction (STEMI). Eptifibatide, a glycoprotein IIb/IIIa inhibitor, is used during percutaneous coronary intervention (PCI) to prevent clots, but its long-term effects in NSTEMI patients remain unclear.
AIMS: This study assesses the impact of Eptifibatide on major adverse cardiac events (MACE) and survival in NSTEMI patients undergoing PCI.
METHODS: A retrospective cohort study of NSTEMI patients treated between 2015 and 2022 at Tehran Heart Center. Patients were grouped based on whether they received Eptifibatide. MACE outcomes were tracked during hospitalization and 1 year later. Statistical adjustments were made for baseline differences.
RESULTS: Among 5309 patients, 12% received Eptifibatide. There were no significant differences between groups in MACE (17.2% vs. 15.6%) or survival (HR 0.97, p = 0.901).
CONCLUSION: Eptifibatide showed no significant effect on MACE or survival in NSTEMI patients undergoing PCI. Further research is needed to explore its role in high-risk subgroups.
AIMS: This study assesses the impact of Eptifibatide on major adverse cardiac events (MACE) and survival in NSTEMI patients undergoing PCI.
METHODS: A retrospective cohort study of NSTEMI patients treated between 2015 and 2022 at Tehran Heart Center. Patients were grouped based on whether they received Eptifibatide. MACE outcomes were tracked during hospitalization and 1 year later. Statistical adjustments were made for baseline differences.
RESULTS: Among 5309 patients, 12% received Eptifibatide. There were no significant differences between groups in MACE (17.2% vs. 15.6%) or survival (HR 0.97, p = 0.901).
CONCLUSION: Eptifibatide showed no significant effect on MACE or survival in NSTEMI patients undergoing PCI. Further research is needed to explore its role in high-risk subgroups.